Microneedle patch-based enzyme-linked immunosorbent assay to quantify protein biomarkers of tuberculosis

IF 3 4区医学 Q3 ENGINEERING, BIOMEDICAL

Biomedical Microdevices Pub Date : 2024-01-30 DOI:10.1007/s10544-024-00694-2

Youngeun Kim, Mary Beth Lewis, Jihyun Hwang, Zheyu Wang, Rohit Gupta, Yuxiong Liu, Tuhina Gupta, James P. Barber, Srikanth Singamaneni, Fred Quinn, Mark R. Prausnitz

{"title":"Microneedle patch-based enzyme-linked immunosorbent assay to quantify protein biomarkers of tuberculosis","authors":"Youngeun Kim, Mary Beth Lewis, Jihyun Hwang, Zheyu Wang, Rohit Gupta, Yuxiong Liu, Tuhina Gupta, James P. Barber, Srikanth Singamaneni, Fred Quinn, Mark R. Prausnitz","doi":"10.1007/s10544-024-00694-2","DOIUrl":null,"url":null,"abstract":"<div><p>There is a clinical need for differential diagnosis of the latent versus active stages of tuberculosis (TB) disease by a simple-to-administer test. Alpha-crystallin (Acr) and early secretory antigenic target-6 (ESAT-6) are protein biomarkers associated with the latent and active stages of TB, respectively, and could be used for differential diagnosis. We therefore developed a microneedle patch (MNP) designed for application to the skin to quantify Acr and ESAT-6 in dermal interstitial fluid by enzyme-linked immunosorbent assay (ELISA). We fabricated mechanically strong microneedles made of polystyrene and coated them with capture antibodies against Acr and ESAT-6. We then optimized assay sensitivity to achieve a limit of detection of 750 pg/ml and 3,020 pg/ml for Acr and ESAT-6, respectively. This study demonstrates the feasibility of an MNP-based ELISA for differential diagnosis of latent TB disease.</p><h3>Graphical abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":490,"journal":{"name":"Biomedical Microdevices","volume":"26 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Microdevices","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s10544-024-00694-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

There is a clinical need for differential diagnosis of the latent versus active stages of tuberculosis (TB) disease by a simple-to-administer test. Alpha-crystallin (Acr) and early secretory antigenic target-6 (ESAT-6) are protein biomarkers associated with the latent and active stages of TB, respectively, and could be used for differential diagnosis. We therefore developed a microneedle patch (MNP) designed for application to the skin to quantify Acr and ESAT-6 in dermal interstitial fluid by enzyme-linked immunosorbent assay (ELISA). We fabricated mechanically strong microneedles made of polystyrene and coated them with capture antibodies against Acr and ESAT-6. We then optimized assay sensitivity to achieve a limit of detection of 750 pg/ml and 3,020 pg/ml for Acr and ESAT-6, respectively. This study demonstrates the feasibility of an MNP-based ELISA for differential diagnosis of latent TB disease.

Graphical abstract

Abstract Image

查看原文本刊更多论文

基于微针贴片的酶联免疫吸附测定法量化结核病的蛋白质生物标记物。

临床上需要通过一种简单易用的检测方法来鉴别诊断肺结核（TB）疾病的潜伏期和活动期。α-结晶素（Acr）和早期分泌抗原靶标-6（ESAT-6）分别是与肺结核潜伏期和活动期相关的蛋白质生物标志物，可用于鉴别诊断。因此，我们开发了一种用于皮肤的微针贴片（MNP），通过酶联免疫吸附试验（ELISA）定量检测皮肤间质中的 Acr 和 ESAT-6。我们用聚苯乙烯制造了机械强度很高的微针，并在其上涂上了针对 Acr 和 ESAT-6 的捕获抗体。然后，我们优化了检测灵敏度，使 Acr 和 ESAT-6 的检测限分别达到 750 pg/ml 和 3,020 pg/ml。这项研究证明了基于 MNP 的 ELISA 用于潜伏肺结核病鉴别诊断的可行性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical Microdevices 工程技术-工程：生物医学

CiteScore

6.90

自引率

3.60%

发文量

审稿时长

6 months

期刊介绍： Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology is an interdisciplinary periodical devoted to all aspects of research in the medical diagnostic and therapeutic applications of Micro-Electro-Mechanical Systems (BioMEMS) and nanotechnology for medicine and biology. General subjects of interest include the design, characterization, testing, modeling and clinical validation of microfabricated systems, and their integration on-chip and in larger functional units. The specific interests of the Journal include systems for neural stimulation and recording, bioseparation technologies such as nanofilters and electrophoretic equipment, miniaturized analytic and DNA identification systems, biosensors, and micro/nanotechnologies for cell and tissue research, tissue engineering, cell transplantation, and the controlled release of drugs and biological molecules. Contributions reporting on fundamental and applied investigations of the material science, biochemistry, and physics of biomedical microdevices and nanotechnology are encouraged. A non-exhaustive list of fields of interest includes: nanoparticle synthesis, characterization, and validation of therapeutic or imaging efficacy in animal models; biocompatibility; biochemical modification of microfabricated devices, with reference to non-specific protein adsorption, and the active immobilization and patterning of proteins on micro/nanofabricated surfaces; the dynamics of fluids in micro-and-nano-fabricated channels; the electromechanical and structural response of micro/nanofabricated systems; the interactions of microdevices with cells and tissues, including biocompatibility and biodegradation studies; variations in the characteristics of the systems as a function of the micro/nanofabrication parameters.